SET Protein Emerges as Target to Restore PP2A and Radiosensitize Glioblastoma

The team examined three PP2A-suppressing proteins—ANP32A, CIP2A, and SET—in cell lines and mouse xenografts. Suppressing SET produced the strongest reduction in tumor initiation, while combined interference with the trio increased radiation-induced apoptosis. These experiments used standard glioblastoma lines and orthotopic implants rather than patient-derived material, limiting immediate translational weight. The approach aims to restore PP2A activity already known to restrain oncogenic signaling and DNA-damage repair, thereby amplifying existing therapies instead of replacing them.

Context from prior work shows PP2A inactivation occurs across multiple aggressive cancers, yet glioblastoma’s rapid adaptation has made single-pathway targeting difficult. The current findings align with earlier observations that CIP2A overexpression correlates with poor radiation response, extending the pattern to SET. By focusing on an FDA-approved antipsychotic known to activate PP2A, the group implicitly tests repurposing feasibility, though off-target effects and blood-brain-barrier penetration remain unaddressed in the reported data.

Next steps center on developing selective SET antagonists and confirming safety in larger animal cohorts before any human trial. If SET inhibition proves additive with temozolomide-radiation regimens, it could shift standard care toward biomarker-selected combination strategies rather than uniform chemoradiation.